{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T15:18:20Z","timestamp":1769527100872,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NCI"},{"DOI":"10.13039\/100000006","name":"Office of Naval Research","doi-asserted-by":"publisher","award":["N00014-06-1-0704"],"award-info":[{"award-number":["N00014-06-1-0704"]}],"id":[{"id":"10.13039\/100000006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000006","name":"Office of Naval Research","doi-asserted-by":"publisher","award":["N00014-08-1-0058"],"award-info":[{"award-number":["N00014-08-1-0058"]}],"id":[{"id":"10.13039\/100000006","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Allos, Inc."},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Angioblast"},{"DOI":"10.13039\/100006413","name":"Ariad","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006413","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001738","name":"Be The Match Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007501","name":"Blue Cross and Blue Shield Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007501","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Buchanan Family Foundation"},{"DOI":"10.13039\/100006432","name":"CaridianBCT","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006432","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002815","name":"CellGenix GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002815","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Children's Leukemia Research Association"},{"name":"Fresenius-Biotech North America, Inc."},{"name":"Gamida Cell Teva Joint Venture Ltd."},{"DOI":"10.13039\/100004328","name":"Genentech, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Genzyme Corporation"},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004072","name":"Kiadis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004072","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"The Leukemia & Lymphoma Society","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Medical College of Wisconsin"},{"name":"Millennium Pharmaceuticals, Inc."},{"name":"Milliman USA, Inc."},{"DOI":"10.13039\/501100004176","name":"Miltenyi Biotec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004176","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Marrow Donor Program"},{"name":"Optum Healthcare Solutions, Inc."},{"DOI":"10.13039\/100009155","name":"Otsuka America Pharmaceutical, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009155","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010293","name":"Seattle Genetics","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010293","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009996","name":"Sigma-Tau Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009996","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Soligenix, Inc."},{"DOI":"10.13039\/501100012112","name":"Swedish Orphan Biovitrum","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012112","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007163","name":"Therakos","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007163","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004382","name":"WellPoint","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.bbmt.2014.12.010","type":"journal-article","created":{"date-parts":[[2014,12,19]],"date-time":"2014-12-19T08:07:55Z","timestamp":1418976475000},"page":"552-558","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Comparison of Outcomes of Allogeneic Transplantation for Chronic Myeloid Leukemia with Cyclophosphamide in Combination with Intravenous Busulfan, Oral Busulfan, or Total Body Irradiation"],"prefix":"10.1016","volume":"21","author":[{"given":"Edward A.","family":"Copelan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belinda R.","family":"Avalos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwang Woo","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaochun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert Peter","family":"Gale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Grunwald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Betty K.","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory A.","family":"Hale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David I.","family":"Marks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edmund K.","family":"Waller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bipin N.","family":"Savani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciano J.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muthalagu","family":"Ramanathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Yves","family":"Cahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Jean","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"Weisdorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Inamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rammurti T.","family":"Kamble","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry C.","family":"Schouten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baldeep","family":"Wirk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark R.","family":"Litzow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud D.","family":"Aljurf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koen W.","family":"van Besien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celalettin","family":"Ustun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian J.","family":"Bolwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher N.","family":"Bredeson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omotayo","family":"Fasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nilanjan","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary M.","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mukta","family":"Arora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Szer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison W.","family":"Loren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edwin P.","family":"Alyea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard T.","family":"Maziarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matt E.","family":"Kalaycio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wael","family":"Saber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2014.12.010_bib1","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0140-6736(82)92735-0","article-title":"Treatment of chronic granulocytic leukemia in chronic phase by allogeneic marrow transplantation","volume":"2","author":"Clift","year":"1982","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2014.12.010_bib2","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S0140-6736(82)92736-2","article-title":"Marrow transplantation for patients in the chronic phase of chronic granulocytic leukemia","volume":"2","author":"Goldman","year":"1982","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2014.12.010_bib3","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1056\/NEJM198601233140403","article-title":"Bone marrow transplantation for patients with chronic myeloid leukemia","volume":"314","author":"Goldman","year":"1986","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2014.12.010_bib4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.7326\/0003-4819-104-2-155","article-title":"Marrow transplantation for the treatment of chronic myelogenous leukemia","volume":"104","author":"Thomas","year":"1986","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bbmt.2014.12.010_bib5","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1182\/blood.V80.5.1352.1352","article-title":"Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy 2","volume":"80","author":"Biggs","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.12.010_bib6","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1182\/blood.V84.6.2036.2036","article-title":"Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide","volume":"84","author":"Clift","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.12.010_bib7","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1182\/blood.V85.8.2263.bloodjournal8582263","article-title":"Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM)","volume":"85","author":"Devergie","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.12.010_bib8","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/clpt.1983.134","article-title":"Busulfan kinetics","volume":"34","author":"Ehrsson","year":"1983","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bbmt.2014.12.010_bib9","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1177\/0091270012447196","article-title":"Variation in prescribing patterns and therapeutic drug monitoring of intravenous busulfan in pediatric hematopoietic cell transplant recipients","volume":"53","author":"McCune","year":"2013","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.bbmt.2014.12.010_bib10","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF00694339","article-title":"Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation","volume":"25","author":"Grochow","year":"1989","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bbmt.2014.12.010_bib11","first-page":"31","article-title":"Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics","volume":"16","author":"Slattery","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.12.010_bib12","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1182\/blood.V89.8.3055","article-title":"Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation","volume":"89","author":"Slattery","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.12.010_bib13","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/FTD.0b013e31829dc940","article-title":"Thirteen years' experience of pharmacokinetic monitoring and dosing of busulfan: can the strategy be improved?","volume":"36","author":"Buffery","year":"2014","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.bbmt.2014.12.010_bib14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2002-08-2619","article-title":"HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen","volume":"102","author":"Radich","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.12.010_bib15","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/bbmt.2002.v8.pm11939604","article-title":"Conditioning therapy with intravenous busulfan and cyclophosphamide (i.v. BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study","volume":"8","author":"Andersson","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.12.010_bib16","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1053\/bbmt.2002.v8.pm12374454","volume":"8","author":"Kashyap","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.12.010_bib17","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1200\/JCO.2013.48.8114","volume":"31","author":"Nagler","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2014.12.010_bib18","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1182\/blood-2013-07-514448","article-title":"Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared to TBI","volume":"122","author":"Copelan","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.12.010_bib19","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1182\/blood-2013-08-519009","article-title":"Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation","volume":"122","author":"Bredeson","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.12.010_bib20","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.bbmt.2008.04.003","article-title":"Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival","volume":"14","author":"Weisdorf","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.12.010_bib21","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.12.010_bib22","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/0002-9343(80)90380-0","article-title":"Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients","volume":"69","author":"Shulman","year":"1980","journal-title":"Am J Med"},{"key":"10.1016\/j.bbmt.2014.12.010_bib23","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cmpb.2007.07.010","article-title":"A\u00a0SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model","volume":"88","author":"Zhang","year":"2007","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1016\/j.bbmt.2014.12.010_bib24","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/bmt.2014.55","article-title":"Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation","volume":"49","author":"Passweg","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.12.010_bib25","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.3324\/haematol.2012.076349","article-title":"Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a global observational study","volume":"98","author":"Gratwohl","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2014.12.010_bib26","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.12.010_bib27","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/sj.bmt.1705063","article-title":"Relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: outcome and prognostic factors: the Chronic Myeloid Leukemia Subcommittee of the GETH (Grupo Espa\u00f1ol de Trasplante Hemopoy\u00e9tico)","volume":"36","author":"Mart\u00ednez","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.12.010_bib28","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1182\/blood-2013-10-530006","article-title":"Busulfan or TBI: answer to an age-old question","volume":"122","author":"Champlin","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.12.010_bib29","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood.V79.10.2578.bloodjournal79102578","article-title":"Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the Group d'Etudes de la Greffe de Moelle Osseuse","volume":"79","author":"Blaise","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.12.010_bib30","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/sj.bmt.1704285","article-title":"Myeloablative conditioning regimens for AML allografts: 30 years later","volume":"32","author":"Gupta","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.12.010_bib31","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1182\/blood-2008-02-141689","article-title":"Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia","volume":"112","author":"Lee","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.12.010_bib32","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1756-8722-3-36","article-title":"Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia","volume":"3","author":"Pidala","year":"2010","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.bbmt.2014.12.010_bib33","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2165\/00003088-200039020-00005","article-title":"Plasma concentration monitoring of busulfan: does it improve clinical outcome?","volume":"39","author":"McCune","year":"2000","journal-title":"Clin Pharm"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879114014104?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879114014104?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:51:20Z","timestamp":1761058280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879114014104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S1083879114014104"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2014.12.010","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of Outcomes of Allogeneic Transplantation for Chronic Myeloid Leukemia with Cyclophosphamide in Combination with Intravenous Busulfan, Oral Busulfan, or Total Body Irradiation","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2014.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}